Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

SIMPLE SUMMARY: Patients with Anaplastic lymphoma kinase (ALK)-positive lung cancer after progression of ALK-tyrosine kinase inhibitor have limited treatment options. This study shows clinical efficacy of the combination of alectinib and bevacizumab with acceptable toxicity in patients with ALK-posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Satoshi, Sakai, Kazuko, Matsumoto, Naoya, Koshio, Jun, Ishida, Akira, Abe, Tetsuya, Ishikawa, Daisuke, Tanaka, Tomohiro, Aoki, Ami, Kajiwara, Tomosue, Koyama, Kenichi, Miura, Satoru, Goto, Yuka, Sekiya, Tomoki, Suzuki, Ryo, Kushiro, Kohei, Fujisaki, Toshiya, Yanagimura, Naohiro, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Saida, Yu, Yoshizawa, Hirohisa, Nishio, Kazuto, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818646/
https://www.ncbi.nlm.nih.gov/pubmed/36612200
http://dx.doi.org/10.3390/cancers15010204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818646/
https://www.ncbi.nlm.nih.gov/pubmed/36612200
http://dx.doi.org/10.3390/cancers15010204

Ejemplares similares